NAD+ vs SNAP-8 (Acetyl Octapeptide-3)
A neutral, side-by-side comparison of two anti-aging & longevity peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
NAD+
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme essential to cellular metabolism, DNA repair, and mitochondrial function. Levels decline with age. Research focuses on restoring NAD+ through precursors (NMN, NR) or direct IV/subcutaneous administration to support longevity and energy metabolism.
Full profileSNAP-8 (Acetyl Octapeptide-3)
8-amino acid cosmetic peptide active (Acetyl Octapeptide-3) that competes with SNARE complex proteins to reduce neuromuscular signal transmission in facial expression muscles. An extended, more potent version of Argireline (Acetyl Hexapeptide-3). Clinical studies show 26–63% reduction in expression wrinkle depth with twice-daily application, positioning it as a topical botulinum toxin alternative.
Full profile| NAD+ | SNAP-8 (Acetyl Octapeptide-3) | |
|---|---|---|
| Category | Anti-Aging & Longevity | Anti-Aging & Longevity |
| Also known as | Nicotinamide Adenine Dinucleotide, NAD, NAD+ precursor | Leuphasyl, Acetyl Octapeptide-3, SNAP-8 peptide, Argireline extension, Acetyl Glutamyl Heptapeptide-3 |
| Evidence | Preclinical only | Research-stage |
| Dosing range | 250mg–1000mg mg, daily (oral precursors) or weekly/monthly (IV/SubQ) | 1%–10% %, twice daily topical application |
| Administration | Oral (precursors: NMN or NR), Intravenous infusion, Subcutaneous injection, Intranasal | Topical (serum/cream) |
| Key side effects | Flushing (especially IV), Chest tightness during rapid IV infusion, Nausea, Fatigue (transient, day of infusion) | Very well-tolerated, Rare mild skin irritation or redness, No systemic absorption at cosmetic concentrations, No paralysis risk (partial SNARE competition only) |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: NAD+ is preclinical only, while SNAP-8 (Acetyl Octapeptide-3) is research-stage.
- Administration: NAD+ — Oral (precursors: NMN or NR), Intravenous infusion, Subcutaneous injection, Intranasal; SNAP-8 (Acetyl Octapeptide-3) — Topical (serum/cream).
- Dosing units differ: NAD+ is dosed in mg, SNAP-8 (Acetyl Octapeptide-3) in % — they operate at different scales.
- Frequency: NAD+ is typically daily (oral precursors) or weekly/monthly (IV/SubQ); SNAP-8 (Acetyl Octapeptide-3) is twice daily topical application.
How each works
NAD+
NAD+ is required for over 500 enzymatic reactions including those catalyzed by sirtuins (longevity-associated proteins) and PARPs (DNA repair enzymes). Rodent studies consistently show that restoring NAD+ levels reverses aspects of metabolic aging. Human trials with NAD+ precursors (NMN, NR) show improved muscle function, insulin sensitivity, and mitochondrial capacity in older adults.
SNAP-8 (Acetyl Octapeptide-3)
SNAP-8 mimics the N-terminal domain of SNAP-25, competing for SNARE complex assembly required for acetylcholine vesicle fusion at the neuromuscular junction. This partial inhibition reduces muscle contraction intensity without complete paralysis. Clinical studies demonstrate statistically significant reductions in crow's feet and forehead line depth after 28 days of use at 5–10% concentration.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.